Get the Stockscreener App
1.5332
0.32%
-0.0168
Therapeuticsmd Inc stock is traded at $1.5332, with a volume of 4,701.
It is down -0.32% in the last 24 hours and down -5.94% over the past month.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
See More
Previous Close:
$1.55
Open:
$1.56
24h Volume:
4,701
Relative Volume:
0.34
Market Cap:
$17.99M
Revenue:
$996.00K
Net Income/Loss:
$-6.09M
P/E Ratio:
0.3415
EPS:
4.49
Net Cash Flow:
$-9.76M
1W Performance:
-1.59%
1M Performance:
-5.94%
6M Performance:
-17.82%
1Y Performance:
-30.09%
1-Day Range:
$1.5201
$1.5647
1-Week Range:
$1.52
$1.5854
52-Week Range:
$1.4302
$3.07
Therapeuticsmd Inc Stock (TXMD) Company Profile
Name
Therapeuticsmd Inc
Sector
Phone
561-961-1900
Address
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-20 | Downgrade | Jefferies | Hold → Underperform |
| May-19-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-02-19 | Initiated | Guggenheim | Buy |
| Oct-17-19 | Initiated | H.C. Wainwright | Buy |
| Apr-30-19 | Resumed | Noble Capital Markets | Outperform |
| Jun-15-18 | Initiated | JP Morgan | Overweight |
| Sep-08-17 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-11-17 | Upgrade | Oppenheimer | Perform → Outperform |
| May-09-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-22-16 | Resumed | Jefferies | Buy |
| Nov-22-16 | Initiated | Oppenheimer | Outperform |
| Nov-07-16 | Resumed | Guggenheim | Buy |
| Apr-04-16 | Initiated | Goldman | Buy |
| Dec-08-15 | Reiterated | Jefferies | Buy |
| Dec-08-15 | Reiterated | Stifel | Buy |
| Sep-21-15 | Reiterated | Jefferies | Buy |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Jul-08-14 | Initiated | FBR Capital | Outperform |
| Apr-17-14 | Reiterated | Noble Financial | Buy |
| Jan-28-14 | Reiterated | Noble Financial | Buy |
View All
Therapeuticsmd Inc Stock (TXMD) Latest News
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD Inc. stock remains steady Thursday, still outperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Tuesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Thursday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock remains steady Thursday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock remains steady Friday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Sexual Wellness Market to Witness 4.7% CAGR by 2031 | SkyQuest Technology - Benzinga
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD announces revised shareholder proposal deadline By Investing.com - Investing.com Australia
TherapeuticsMD announces revised shareholder proposal deadline - Investing.com India
Tourmaline Bio (NASDAQ:TRML) Shares Up 3.9% - Defense World
This company generates no revenue and its market cap is over $20 billion. Here's why that valuation - The Bharat Express News
Commonwealth Equity Services LLC Has $979,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX) - Defense World
WINTON GROUP Ltd Buys New Shares in Tactile Systems Technology, Inc. (NASDAQ:TCMD) - MarketBeat
TransMedics Stock: Take Profits While The Valuation Is Sky High (NASDAQ:TMDX) - Seeking Alpha
Somite’s SMT-M01 awarded US orphan drug designation for Duchenne muscular dystrophy - BioWorld Online
Transmedics Group Inc (TMDX) deserves deeper analysis - US Post News
This is why everyone is talking about Summit TherapeuticsTHE BHARAT EXPRESS NEWS - The Bharat Express News
Here's Why Everyone's Talking About Summit Therapeutics - The Motley Fool
An analyst sees good growth prospects for Transmedics Group Inc (TMDX) - SETE News
Implant maker Tenon Medical nearly triples its market capitalization in two days - Kursiv Media
TD Asset Management Inc Invests $2.08 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit lifts Instil, BioNTech on Merck beating data (NASDAQ:SMMT) - Seeking Alpha
Therapeuticsmd Inc Stock (TXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Therapeuticsmd Inc Stock (TXMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
| Walker Marlan D | Chief Executive Officer |
Dec 05 '23 |
Option Exercise |
0.00 |
70,000 |
0 |
81,615 |
| Walker Marlan D | Chief Executive Officer |
Dec 06 '23 |
Sale |
2.31 |
14,500 |
33,496 |
67,115 |
| Walker Marlan D | Chief Executive Officer |
Dec 07 '23 |
Sale |
2.24 |
4,550 |
10,187 |
62,565 |
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):